| Date | Title | Description |
| 01.08.2025 | Life Sciences on the Chinese Mainland – Vital signs: Diagnosing trends in the life sciences real estate market on the Chinese mainland | HONG KONG SAR – Media OutReach Newswire – 1 August 2025 – Cushman & Wakefield, a leading global real estate services firm, today released its Life Sciences on the Chinese Mainland – Vital signs: Diagnosing trends in the life sciences re... |
| 25.07.2025 | Hong Kong biotech enters its second act with a licensing supercycle | As summer arrives, the rally in Hong Kong-listed biotech stocks is still going strong.
In the first half of the year, companies like Harbour BioMed (HBM), Jacobio Pharmaceuticals, and 3SBio saw their share prices more than triple, with seve... |
| 07.04.2025 | As Chinese Pharma Stocks Dive, Insiders Say Novel Drug Deals Remain Untouched by US Tariff Hike | (Yicai) April 7 -- The sharp selloff in Chinese pharmaceutical stocks was mainly due to market panic after the US jacked up the import tax on Chinese goods by more than expected, according to industry sources, who pointed out that innovativ... |
| 24.03.2025 | China’s biotech sector is undervalued given its AI-driven opportunities: Investor | - |
| 28.02.2025 | BeiGene Jumps After Drugmaker Narrows Annual Loss by 26% | (Yicai) Feb. 28 -- BeiGene's stock rose after the biotech company reported its net loss shrank 26 percent last year from the prior one while turning its first positive adjusted operating profit driven by a surge in revenue.
Shares of BeiGen... |
| 13.11.2024 | China's BeiGene Blows Past 2023 Earnings in Just Nine Months, Propelled by Cancer Drugs | (Yicai) Nov. 13 -- Chinese oncology firm BeiGene significantly boosted its revenue in the first three quarters of this year, surpassing its total revenue from last year, while also narrowing its losses, thanks to two successful cancer treat... |
| 04.11.2024 | MoonFox Analysis | Chinese A-share Companies' Global Revenue Journey: Expected to Reach US $1.4 Trillion | SHENZHEN, China, Nov. 4, 2024 /PRNewswire/ -- Since the Reform and Opening-up in China, global trade has been vital to China's economic growth. Data indicates that China's total import and export trade volume steadily increased, reaching CN... |
| 30.09.2024 | The Rising Tide of Chinese Biopharmaceuticals: A Global Perspective | The biopharmaceutical landscape is shifting. Chinese companies are no longer just local players; they are emerging as global contenders. The recent collaboration between Anbogen and BeiGene exemplifies this trend. Anbogen, a clinical-stage ... |
| 28.09.2024 | Frost & Sullivan Released Report: "2024 Blue Book on Chinese Biopharmaceuticals Going Global: Current Status and Trends" | SHANGHAI, Sept. 28, 2024 /PRNewswire/ -- Frost & Sullivan released the "2024 Blue Book on Chinese Biopharmaceuticals Going Global: Current Status and Trends" which focus on the progress of Chinese biopharmaceuticals going glob... |
| 27.09.2024 | Anbogen Announces Drug Supply Collaboration with BeiGene to Evaluate Combination Therapy in Colorectal Cancer | TAIPEI, Sept. 27, 2024 /PRNewswire/ -- Anbogen, a clinical-stage biotech company, today announced a drug supply collaboration to evaluate the combination of Anbogen's HDAC inhibitor, ABT-301, with BeiGene's anti-PD-1 antibody tislelizumab, ... |
| 13.09.2024 | Breaking Barriers: The Fight Against Lymphoma and Bladder Cancer | In the realm of cancer awareness, two significant events recently unfolded, shining a light on the emotional and physical battles faced by patients. On one hand, World Lymphoma Awareness Day (WLAD) took center stage, while on the other, a g... |
| 13.09.2024 | BeiGene Singapore Raises Awareness for World Lymphoma Awareness Day 2024: It's Time for Honest Talk | SINGAPORE, Sept. 13, 2024 /PRNewswire/ -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, is proud to join the global community in raising awareness about lymphoma on World Lymphoma Awareness Day (WLAD). L... |
| 03.09.2024 | SKIES ACROSS NORTH AMERICA TO LIGHT UP THIS FALL IN SUPPORT OF BLOOD CANCER PATIENTS | The Leukemia & Lymphoma Society kicks off philanthropic campaign Light The Night; communities nationwide encouraged to learn why awareness and support is critical
RYE BROOK, N.Y., Sept. 3, 2024 /PRNewswire/ -- The Leukemia & Lymphom... |
| 28.08.2024 | A New Dawn in Lung Cancer Treatment: GenFleet's KRAS G12C Inhibitor Approved in China | In a groundbreaking move for cancer treatment, GenFleet Therapeutics has received approval from China's National Medical Products Administration (NMPA) for its KRAS G12C inhibitor, Dupert® (fulzerasib). This marks a significant milestone in... |
| 23.08.2024 | GenFleet Announces the First Approval of a KRAS G12C Inhibitor in China for Treatment of Advanced Non-small Cell Lung Cancer Patients Harboring KRAS G12C Mutation | SHANGHAI, Aug. 23, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced China's National Medical Products Administration has approved Dup... |
| 06.08.2024 | Lymphoma Research Foundation to Honor Longtime Foundation Supporter and Past Board Chair Steven J. Prince at Annual Gala on September 25 | Lymphoma Research Foundation Logo
BeiGene will be presented with the Lymphoma Research Foundation's Corporate Leadership Award for excellence in development of next-generation cancer treatments
NEW YORK, Aug. 6, 2024 /PRNewswire-PRWeb/ -- T... |
| 10.07.2024 | Frost & Sullivan Institute Honors Global Companies with the Enlightened Growth Leadership Best Practices Recognition, 2024 | SANTA CLARA, Calif., July 10, 2024 /PRNewswire/ -- The Frost & Sullivan Institute is excited to announce the winners of the 2024 Enlightened Growth Leadership Best Practices Recognition from the Americas. This prestigious accolade honor... |
| 21.06.2024 | Biocytogen Awarded U.S. Patent for RenLite® Common Light Chain Mouse Platform | BEIJING, June 21, 2024 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced United States Patent and Trademark Office (USPTO) patent grant for independently developed RenLite® fully ... |
| 14.03.2024 | Pi Health Secures $30M to Democratize Cancer Clinical Trials | Pi Health Co-Founders Bobby Reddy, MD, COO & Geoff Kim, CEO (left to right)
What You Should Know:
– Pi Health, a newly independent oncology-focused clinical research company raises $30M in Series A funding led by AlleyCorp and Obvious V... |
| 10.03.2024 | Blockbuster BeiGene Cancer Drug Adds Another FDA Approval | A BeiGene drug already used to treat several types of blood cancer now has an additional FDA approval as a treatment for follicular lymphoma. The regulatory decision makes the BeiGene drug the first in its class for treating this type of ca... |
| 12.07.2023 | Putting Patients First: The Quest to Make Anticancer Cell Therapy Accessible to All | TAIPEI, July 12, 2023 /PRNewswire/ -- As cell therapies continue to rank among the most expensive of cancer treatments, BeiGene is quietly charting a different path that would enable more equitable access for all.
Right: Dr. Alex Huang, Vic... |
| 03.02.2023 | New Talk About It Resources Aim to Accelerate Integration of Mental Health into Quality Cancer Care | BeiGene Releases Report and Launches CancerandMentalHealth.com in Conjunction with World Cancer Day to Help Patients and Caregivers Overcome Barriers to Access
BeiGene, a global biotechnology company, has released a report highlighting the ... |
| 27.06.2022 | Antengene Announces Clinical Trial Collaboration with BeiGene to Evaluate Selinexor in Combination with Tislelizumab in T and NK-Cell Lymphoma | - Selinexor is an oral small molecule XPO1 inhibitor; tislelizumab is an anti-PD-1 checkpoint inhibitor
SHANGHAI and HONG KONG, June 27, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading inn... |
| 18.12.2021 | BeiGene : Announces Closing of Its RMB22.2 Billion (US$3.5 Billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China - Form 8-K | BeiGene Announces Closing of Its RMB22.2 Billion (US$3.5 Billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
RMB Shares begin trading on the STAR Market under the stock code "688235", making... |
| 15.12.2021 | BeiGene Announces Closing of Its RMB22.2 Billion (US$3.5 Billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China | BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announce... |
| 07.12.2021 | BeiGene : Announces Pricing of its RMB22.2 billion (US$3.5 billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China - Form 8-K | BeiGene Announces Pricing of its RMB22.2 billion (US$3.5 billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
CAMBRIDGE, Mass. & BEIJING - November 3, 2021 - BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 0616... |
| 30.11.2021 | BeiGene Announces Pricing of its RMB22.2 billion (US$3.5 billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China | BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced the pricing... |
| 02.09.2021 | FDA approves BeiGene's Brukinsa in rare blood cancer amid company's US expansion plans | BeiGene has been anything but shy about its US expansion plans centered around blood cancer drug Brukinsa. To see those plans through, BeiGene will have to go right at AbbVie and J&J’s Imbruvica, and Brukinsa now has one mor... |
| 31.08.2021 | In a major blow to vaccine efforts, senior FDA leaders stepping down | A group of powerhouse biotech leaders is coming together to launch a new nonprofit, one aimed at delivering therapies to rare disease populations they believe pharma is leaving behind.
Jim Wilson, the famed gene therapy researcher, teamed u... |
| 02.08.2021 | Drug supplier Abcam brings a longtime collaborator in house as part of $340M buyout pact | BeiGene blazed the trail for a growing wave of Chinese oncology drugs breaking through in the US with an initial approval for BTK inhibitor Brukinsa back in 2019, and now the US/Chinese drugmaker has set the stage for its lead drug’s next b... |
| 17.06.2021 | BEIGENE, LTD.
BeiGene : Announces First Patient Dosed in Global Phase 3 Trial of Anti-TIGIT Antibody Ociperlimab in Non-Small Cell Lung Cancer | BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the first patient was dosed in the global Phase 3 AdvanTIG-302 trial of... |
| 03.06.2021 | ZHONGCHAO INC.
Zhongchao Inc. : Announces the On-Going One-Year Leukemia Education Project with Bethune Foundation and BeiGene Shanghai | SHANGHAI, June 3, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a healthcare services company offering online healthcare information, professional training and educational services, a... |
| 02.03.2021 | Health Canada Approves BRUKINSA® (Zanubrutinib) for the Treatment of Waldenström’s Macroglobulinemia | CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--Mar 2, 2021--
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced tha... |
| 26.02.2021 | BeiGene Announces Closing of Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and Japan | CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--Feb 26, 2021--
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced th... |
| 01.12.2020 | Chinese edtech startup EEO Education gains US$ 265M in Series C funding | EEO Education was founded in 2014 and launched its first online classroom software, ClassIn, in 2015. The software initially targeted after-school education companies such as New Oriental and TAL Education. But its software is now being use... |
| 22.10.2020 | Biden And Trump Drug Pricing Policies Would Decimate Biotech, Drive Innovation To China | President Donald Trump signs an executive order linking drug prices to rates paid in other ... [+] countries. Photographer: Stefani Reynolds/Bloomberg© 2020 Bloomberg Finance LP |
| 01.09.2020 | STAT China: Lineup for Hong Kong IPO grows, and a conversation with Junshi’s Li Ning | A version of this digest first appeared in the weekly STAT China newsletter. To receive future editions, sign up here.
Happy Tuesday and welcome back to STAT China. The CEO of Junshi Biosciences joins us for our latest “newsmaker” interview... |
| 29.05.2020 | As tislelizumab gains traction in China, BeiGene pulls the curtain on NSCLC data supporting the PD-1 drug | In a world now brimming with checkpoint inhibitors, companies often struggle to make a mark given a raft of therapies have already captured a considerable portion of the vast oncology market.
BeiGene’s tislelizumab was ... |
| 14.05.2020 | Private Sector Tracker: How Asia’s Companies Are Responding To The COVID-19 Pandemic | SeegeneSHIN IN-SEOP/FORBES KOREA |
| 14.04.2020 | BeiGene reports positive Phase III interim analysis for lung cancer drug | The company said it plans to file for approval of the drug with Chinese drug regulators and present data from the study at upcoming medical conferences. Shares of BeiGene were up around 6% on the Nasdaq in Tuesday afternoon trading, followi... |
| 01.04.2020 | Coronavirus Business Tracker: How The Private Sector Is Fighting The Covid-19 Pandemic | Alain Mérieux, founder of BioMérieux.AFP via Getty Images |
| 16.12.2019 | BeiGene’s Phase III Waldenström’s study misses mark, but with a possible silver lining | Shares of BeiGene were down more than 7% on the Nasdaq Monday afternoon.
ASPEN’s primary endpoint was efficacy, as measured by the rate of patients who achieved a complete response or very good partial response, also known as CR and VGPR, r... |
| 22.11.2019 | Zymeworks & BeiGene Advance ZW25 into Potentially Registration-Enabling Global Studies | SINGAPORE — Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced updated Phase 1 data for single-agent ZW25 in heavily pretreated patients with HER2‑expressing soli... |
| 05.11.2019 | Steve Kafka joins Section 32 as managing partner; Takeda auctions off $660M drug portfolio in bid to reduce post-Shire M&A debt load | Steven Kafka
→ Former Thrive CEO and partner at Third Rock Ventures, Steve Kafka, has hopped aboard Section 32 as a managing partner. Within his new role, Kafka “will focus on supporting and expanding the firm’s investment... |
| 01.11.2019 | Amgen takes out big stake in BeiGene for $2.7B in strategic partnership | Shares of BeiGene were up 30 percent on the Nasdaq Friday morning following the announcement. Shares of Amgen were up slightly more than 1 percent.
The aforementioned drugs are respectively used to treat acute lymphoblastic leukemia, multip... |
| 13.02.2019 | For a Chinese cancer drug developer, Bristol-Celgene deal is poised to have big ripple effects | SAN FRANCISCO — Celgene is famous for cultivating a constellation of biotech partners — companies whose fortunes are poised to be shifted by last month’s news that Bristol-Myers Squibb plans to buy Celgene in a $74 billion deal.
One of thos... |
| 15.01.2019 | China’s BeiGene gets FDA breakthrough therapy designation for BTK inhibitor | In MCL, the company has a Phase II clinical trial of 86 patients enrolled at 17 sites in China. BeiGene is based in Beijing and has a US headquarters in Cambridge, Massachusetts.
Zanubrutinib is a BTK inhibitor, belonging to a class that in... |
| 08.08.2018 | BeiGene takes a hit after historic $903M Hong Kong IPO with negative biotech sentiment | The first day of its secondary listing in Hong Kong has proven slightly disappointing for BeiGene.
The Beijing-based cancer drugmaker closed its trading debut down 1% after falling as much as 5% during the day. Despite recru... |
| 02.08.2018 | BeiGene bags a staggering $903M IPO on the HKEX — and still manages to spark some nervous fretting | BeiGene’s secondary IPO on the Hong Kong exchange says a lot about the sky-high expectations of the biotechs lining up to cash in there under more liberal listing rules.
The biotech raised $903 million, and that was on the low en... |
| 27.07.2018 | In for the China biotech gold rush, BeiGene eyes monster $800M-plus Hong Kong IPO | Fast on the heels of Ascletis’ record $400 million raise on the Hong Kong stock exchange, BeiGene is proposing its own IPO in the city — to run parallel with its current listing on Nasdaq. And they aren’t thinking small.
The Bei... |
| 06.07.2017 | Term Sheet — Thursday, July 6 | THREE UNRELATED THINGS
FALSE START: The finance world experienced a big letdown yesterday, after reports that JP Morgan might enter the bidding for Worldpay, a UK-based payment processor worth nearly $10 billion.
Paid Content Your company m... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 16.10.2015 | Chinese cancer immunotherapy player BeiGene files for $100M IPO | Advancing its clinical stage pipeline. BeiGene has an open IND with the U.S. FDA for its BTK inhibitor, and the RAF inhibitor’s been approved for trial in China. BeiGene’s drugs have been tested in Australian and New Zealand in dose escalat... |
| 15.05.2015 | Funding roundup - week ending 5/15/15 | DocPlanner, DocuSign, Grab, Silversheet, Knod, Actiance, NerdWallet, Wave, MarkLogic, Instart Logic
Seed stage
Grab, formerly Grab a Grub, a food-logistics firm, raised a $1 million round of seed funding from Oliphans Capital Haresh Chawla.... |
| 13.05.2015 | BeiGene Completes $US97M Financing | BeiGene Ltd., a Cayman Islands exempted oncology company focused on developing targeted and immuno-oncology therapeutics, completed a $US97m financing.
The round was co-led by Hillhouse Capital and an undisclosed blue chip U.S. public inves... |
| 13.05.2015 | China's BeiGene banks $97M to get its cancer drugs into the clinic | BeiGene CEO John Oyler has long said China has all the world-class science and entrepreneurial ambition necessary to become a biotech hotbed. All that's missing is the kind of venture capital interest startups enjoy on the other side of the... |
| 14.11.2014 | BeiGene Receives $75M in Funding | BeiGene, a Beijing, China-based oncology company, received $75m in funding.
Backers included initial angel and strategic investors and new investors Hillhouse Capital and CITIC Capital Partners, as well as an undisclosed blue chip U.S. publ... |
| - | BeiGene reports positive Phase III interim analysis for lung cancer drug | Interim results from a Phase III clinical trial have shown that patients receiving a cancer immunotherapy drug for a form of lung cancer on top of chemotherapy were more likely than those receiving chemotherapy alone to survive without thei... |
| - | BeiGene Tumbles on Shanghai Star Market Debut, But Still Raises USD3.5 Billion | (Yicai Global) Dec. 15 -- Shares in BeiGene plunged 16.4 percent on their first day of trading on the Shanghai Stock Exchange’s Nasdaq-style Star Market today but the Chinese biopharmaceutical company still managed to achieve the second mos... |
| - | BeiGene’s Phase III Waldenström’s study misses mark, but with a possible silver lining | A Chinese biotech company that just won Food and Drug Administration approval for its lead candidate in a type of lymphoma missed the mark in a Phase III study of the drug in another disease, but some analysts are nevertheless calling it a ... |
| - | Chinese cancer immunotherapy player BeiGene files for $100M IPO | China-based cancer immunotherapy company BeiGene just filed with the SEC for a $100 million IPO, regulatory filings show.
The company’s developed a series of clinical-stage drug monoclonal antibiody candidates that serve as BTK, RAF and PAR... |
| - | BeiGene Initiates Phase 1 Clinical Trial for HPK1 Inhibitor BGB-15025 | CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--Mar 10, 2021--
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced th... |
| - | BeiGene Announces Presentation of Clinical and Preclinical Data at the AACR Annual Meeting 2021 | CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--Mar 10, 2021--
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced mu... |
| - | Amgen takes out big stake in BeiGene for $2.7B in strategic partnership | Biotech company Amgen will acquire more than one-fifth of an up-and-coming Chinese biotech company as part of a deal to expand its oncology presence in China.
The Thousand Oaks, California-based company said Thursday it would acquire a 20.5... |
| - | BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Second- or Third-line Non-Small Cell Lung Cancer | BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 5, 2021--
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced tha... |
| - | BeiGene Reports Fourth Quarter and Full Year 2020 Financial Results | CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--Feb 25, 2021--
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today reported rec... |
| - | Asia-Pacific markets fall ahead of U.S. inflation data | This is CNBC’s live blog covering Asia-Pacific markets. |
| - | China’s BeiGene gets FDA breakthrough therapy designation for BTK inhibitor | A Chinese firm has received breakthrough therapy designation from the Food and Drug Administration for a drug it is investigating as a treatment for non-Hodgkin’s lymphomas and slow-growing leukemia.
BeiGene said Monday that the FDA had gra... |
